Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients

NCT ID: NCT03389997

Last Updated: 2024-04-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-07
• Study Completion Date: 2024-02-15

Brief Summary

The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection. This duration has not been much studied in that population whereas it is probably longer than that in immunocompetent patients. Thereby it may be a source of transmission amongst these immunocompromised patients.

Detailed Description

The development of multiplex polymerase chain reaction (PCR) tests has greatly improved the diagnosis of respiratory tract viral infections by increasing its sensitivity and the diversity of viral species detected. However, there are few data concerning respiratory tract viral infections amongst hematology and oncology patients. Especially, the duration of viral shedding following an infection has not been much studied whereas it is a source of inter-individual transmission between immunocompromised patients who are more likely to develop severe disease.

Studies conducted so far concerned mainly hematology patients. They have shown that viral carriage could last up to one month and a half in some patients with hematological malignancy.

The aim of this study is to determine the duration of the viral shedding in patients from hematology and oncology units after a respiratory tract viral infection for the ten main viruses involved in order to better manage these infections and to better prevent their transmission.

Conditions

Respiratory Tract Viral Infection

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Interventions

nasal swabs

Iterative nasal swabs will be performed to screen for virus shedding

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Patient with solid organ cancer or haematological malignancy with or without chemotherapy
• Having symptoms of upper and/or lower respiratory tract infection
• Virus detected by PCR in nasal sample
• Signature of consent

Exclusion Criteria

• Hematological stem cell and solid organ recipients
• No health insurance
• protected people

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Poitiers University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

France CAZENAVE-ROBLOT, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

CHU of POITIERS

Locations

University Hospital of Poitiers

Poitiers, , France

Countries

France

Other Identifiers

ONCOVIR

Identifier Type: -

Identifier Source: org_study_id